How Safe is the Hypolipidaemic Drug Treatment?

Hellenic Journal of Cardiology

Volumn 43, Issue 6, 2002, Pages 219-225

  Rallidis, Loukianos S ^a,b   Apostolou, Thomas S ^a  

^a GENERAL HOSPITAL OF NIKEA   (Greece)

^b NONE   (Greece)

Author keywords

Hepatoxicity; Myopathy; Safety of hypolipidaemic drugs; Statins

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTILIPEMIC AGENT; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; CERIVASTATIN; CREATINE KINASE; CYTOCHROME P450 3A4; ELTINA; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOBAN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MEVINOLIN; PLACEBO; PRAVASTATIN; SIMVASTATIN;

BRAIN HEMORRHAGE; CARCINOGENESIS; CLINICAL TRIAL; CONSTIPATION; CORONARY ARTERY DISEASE; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERCHOLESTEROLEMIA; INDIGESTION; INSOMNIA; LIVER TOXICITY; MORTALITY; MUSCLE WEAKNESS; MYALGIA; MYOPATHY; MYOSITIS; NAUSEA; NIGHTMARE; PERIPHERAL NEUROPATHY; PRIMARY PREVENTION; RASH; REVIEW; RHABDOMYOLYSIS; SECONDARY PREVENTION; SUICIDE;

EID: 0842269004     PISSN: 10117970     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, et al, for the West of Scotland Coronary Prevention Study Group: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-1307.
2. Scandinavian Simvastatin Survival Study Group: Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Sinvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
3. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al, for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-1009.
4. The long-term intervention with pravastatin in ischaemic disease (LIPID) study group: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol level. N Engl J Med 1998; 339: 1349-1357.
5. Downs JR, Clearfield M, Weis S, Whitney E, et al: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. JAMA 1998; 279: 1615-1622.
6. Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 1975; 231: 360-381.
7. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trials results. Reduction in incidence of coronary heart disease. JAMA 1984; 251: 365-374.
8. Frock MH, Leo O, Haapa K, et al: Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987; 317: 1237-1245.
9. Crouse JR, Byington RP, Furberg CD: HMG-CoA reductase inhibitor therapy and stroke risk reduction: an analysis of clinical trials data. Atherosclerosis 1998; 138: 11-2424.
10. Furberg CD: Natural statins and stroke risk. Circulation 1999; 99: 185-188.
11. Huttunent JK, Heinonen OP, Manninen V, et al: The Helsinki Heart Study: An 8.5-year safety and mortality follow-up. J Intern Med 1994; 235: 31-39.
12. Rubins HB, Robins SJ, Collins D, et al: Gemfibrozil for the secondary prevention of coronary heart disease in the men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999; 341: 410-408.
13. Pedersen R, Wilhelmsen L, Faergeman O, et al: Follow-up study of patients randomized in the Scandinavian Simvastatin Survival Study (4S) of cholesterol lowering. Am J Cardiol 2000; 86: 257-262.
14. Bjerre LM, LeLorier J: Do statins cause cancer? A meta-analysis of large randomized clinical trials. Am J Med 2001; 110: 716-723.
15. Newman A, Clutterbuck RD, Powles RL, Catovsky D, Millar JL: A comparison of the effects of the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors simvastatin, lovastatin and pravistatin on leukaemic and normal bone marrow progenitors. Leuk Lymphoma 1997; 24: 533-537.
16. Larner J, Jane J, Laws E, Packer R, Myers C, Shaffrey M: A phase I-II trial of lovastatin for anaplastic astrocytoma and glioblastoma multiforme. Am J Clin Oncol 1998; 21: 579-583.
17. Shek A, Ferrill MJ: Statin-fibrate combination therapy. Ann Pharmacother 2001; 35: 908-917.
18. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol 2002; 40: 567-572.
19. Knopp RH: Drug treatment of lipid disorders. N Engl J Med 1999; 341: 498-511.
20. Ucar M, Mjorndal T, Dahlqvist R: HMG-CoA reductase inhibitors and myotoxicity. Drug Safety 2000; 22: 441-457.
21. Masters BA, Palmoski MJ, Flint OP, et al: In vitro myotoxicity of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, pravastatin, lovastatin, and simvastatin, using neonatal rat skeletal myocytes. Toxicol Appl Pharmacol 1995; 131: 163-174.
22. Shimada T, Yamazaki H, Mimura M, et al. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994; 270: 414-423.
23. Bottorff M, Hansten P: Long-term safety of hepatic hydroxymethyl glutaryl coenzyme A reductase inhibitors. Arch Intern Med 2000; 160: 2273-2280.
24. Lau TK, Leachman DR, Lufchanowski R: Severe rhabdomyolysis associated with the cerivastatin-gemfibrozil combination therapy: report of a case. Tex Heart Inst J 2001; 28: 142-145.
25. Federman DG, Hussain F, Walters JB, Fatal rhabdomyolysis caused by lipid-lowering therapy. South Med J 2001; 94: 1023-1026.
26. Shepherd J: Fibrates and statins in the treatment of hyperlipidemia: an appraisal of their efficacy and safety. Eur Heart J 1995; 16: 5-13.
27. Gaist D, Rodriguez LAG, Huerta C, Hallas J, Sindrup SH: Lipid-lowering drugs and risk of myopathy: a population-based follow-up study. Epidemiology 2001; 12: 565-569.
28. Keogh A, Macdonald P, Kaan A, Aboyoun C, Spratt P, Mundy J: Efficacy and safety of pravastatin vs simvastatin after cardiac transplantation. J Heart Lung Transplant 2000; 19: 529-537.
29. Rallidis LS, Papasteriades EG: Non-lipid related effects of statins. Hellenic J Cardiol 2001; 42: 403-414.
30. Chan KA, Andrade SE, Boles M, et al: Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women. Lancet 2000; 355: 2185-2188.
31. Jick H, Zomberg GL, Jick SS, Seshadri S, Drachman DA: Statins and the risk of dementia. Lancet 2000; 356: 1627-1631.